Studying liver damage after the Fontan heart procedure in adults
Studies how liver scarring develops in adults who had the Fontan procedure.
Key facts
- Who runs it
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Where
- Bethesda, United StatesSee the site
- Trial code
- Registry title
- Fontan Associated Liver Disease and the Evaluation of Biomarkers for Disease Severity Assessment
- Status
- Recruiting
- People taking part
- 100 people, planned
- Started
- 7 Sept 2022
- Expected to end
- 30 Jun 2051
- Type of study
- Observational
- Record updated
- 13 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who had a Fontan heart operation and may get liver disease from it (FALD). It studies how blood backing up in the liver leads to scarring.
- Age
- 18 Years to 100 Years
- Sex
- Male and female
- Disease stage
- People who had a Fontan procedure for a severe congenital heart disease and are at risk of Fontan associated liver disease.
- Earlier treatment
- Must have had a Fontan procedure. Must have joined the Liver Diseases Branch protocol 91DK0214 before. Must have had a heart catheter test or a liver biopsy through the neck vein within ten years before screening. NIH heart and anaesthesia doctors must approve taking part.
Main reasons for not taking part
- Other liver diseases that can lead to cirrhosis, such as active hepatitis B, hepatitis C, hemochromatosis or autoimmune hepatitis
- Liver cancer or bile duct cancer, or a blocked bile duct
- Active alcohol or drug abuse in the past one year
- Severe allergy to contrast dye, or radiation exposure over 5 rems in the past year
- Being pregnant now
The registry criteria, word for word
Show all 22 criteriaShow less
Who cannot take part
- Bile duct obstruction as suggested by imaging studies done within the previous six months
- Active substance abuse, such as alcohol, inhaled or injection drugs within the previous one year (assessed during patient interviews or by patient self-report)
- Radiation exposure exceeds 5 rems during the past year
- Female subjects who are currently pregnant will be excluded due to radiation exposure necessary for study completion. In addition, altered hemodynamics may confound the study s results. Following pregnancy, patients may be reconsidered for the study
- Evidence of other forms of liver disease that typically result in cirrhosis
- Evidence of hepatocellular carcinoma; either alpha-fetoprotein (AFP) levels greater than 50 ng/ml (normal <6.6 ng/ml) and/or ultrasound (or other imaging study) demonstrating a mass suggestive of liver cancer
- A documented or otherwise stated severe allergic reaction to contrast
- Any other severe condition, which in the opinion of the investigators would impede the patient s participation or compliance in the study
- Evidence of active Chronic Hepatitis B infection as defined by the presence of hepatitis B surface antigen (HBsAg) in serum and elevated HBV DNA (>10,000 IU/mL)
- Hepatitis C as defined by the presence of hepatitis C RNA in serum
- Evidence of other liver disease such as primary sclerosing cholangitis, primary biliary cirrhosis, Wilson s disease, autoimmune hepatitis as defined by either liver histology or laboratory abnormalities
- Hemochromatosis as defined by presence of 3+ or 4+ stainable iron on liver biopsy or homozygosity for C282Y. Patients with iron saturation indices of >45% and serum ferritin levels of >300 ng/ml for men and >250 ng/ml for women will undergo genetic testing for hemochromatosis
- An individual who meets any of the following criteria will be excluded from participation in this study:
- Evidence of Cholangiocarcinoma
- Inability to comply or give written informed consent as there is no direct benefit from participation in this study
Other criteria
- INCLUSION CRITERIA:; In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Male and female subjects >= 18 years of age
- Past surgical history of Fontan procedure
- Prior enrollment in the Liver Diseases Branch protocol 91DK0214
- Underwent cardiac catheterization or transjugular liver biopsy within ten years prior to the date of screening
- Approved to proceed by the NIH Cardiology Consult
- Approved to proceed by the NIH Cardiac Pre-anesthesia Consult
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Where in United States
- National Institutes of Health Clinical CenterBethesda, United StatesContact: Elenita M Rivera, R.N.Taking people
About the trial
What the trial wants to find out
Background:
Read full original descriptionShow less
In Fontan Associated Liver Disease (FALD), congestion of blood in the liver causes cirrhosis. This condition can cause death. Researchers want to understand what triggers this process and find new treatments for it.
Objective:
To understand how long-term congestion of blood in the liver causes liver scarring that eventually leads to cirrhosis.
Eligibility:
People aged 18 and older who are at risk of developing FALD from the Fontan procedure.
Design:
Participants will be screened with:
Medical history
Physical exam
Blood and urine tests
Liver ultrasound. This uses sound waves to take pictures of the body.
Participants will have an outpatient visit within 12 weeks after screening. Within 24 weeks later, they will have a 3-day hospital stay. About 2 weeks later, they will have a follow-up visit.
Visits will include repeats of the screening tests and:
Heart tests
Stool collection
Questionnaires
MRI of the liver. Participants will lie on a bed that slides in and out of the scanner. They will receive a contrast agent injected into a vein. While in the scanner, they will also have an MRCP to view the bile ducts and the pancreatic duct.
Fibroscan exam. This is an ultrasound that uses a special probe to look at the toughness of the liver.
Upper endoscopy. This uses a thin scope to look inside the upper digestive tract.
Liver biopsy. This will be taken through large vein in the neck or through the chest. Just before the biopsy, participants will have pressure measurements inside their liver. For this, a catheter will be inserted into a neck vein and guided into the liver.
The group in the trial
- Adults with FALD
male and female subjects =18 years of age who historically underwent Fontan procedure due to a severe CHD and thus are at risk for FALD by virtue of their altered physiology
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Natural History of Fontan Associated Liver Disease and the Evaluation of Biomarkers for Disease Severity Assessment
- Plain-language title
- Studying liver damage after the Fontan heart procedure in adultsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT05213598, who can take part
- Record updated
- 13 October 2026